Clinical Trial

An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection

Study acronym: Prontogest
Completed Phase 1
View on ClinicalTrials.gov →
Summary
Bioequivalence study of two injectable formulation of progesterone in healthy post-menopausal women
Trial Details
NCT Number NCT07495007
Lead Sponsor Zi Diligence Biocenter
Collaborators: Marcyrl Pharmaceutical Industries
Conditions Bioequivalance, Post-menopause
Enrollment 26 participants
Start Date 2025-11-10
Primary Completion 2025-12-28 (estimated)
Study Completion 2025-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-27